Sorrento Therapeutics, Inc. Stock
Stocks
SRNE
US83587F2020
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
OTC Markets
23/10/2026
|
5-day change | 1st Jan Change | ||
| 0.000100 USD | -66.67% |
|
-80.00% | -96.15% |
| 03-17 | Semnur Pharmaceuticals, Inc. Announces CEO Changes, Effective March 13, 2026 | CI |
| 03-17 | Semnur Pharmaceuticals, Inc. Announces Management Changes | CI |
| Market Cap | 67.15M 59.96M 55.39M 50.2M 93.92M 6.37B 95.47M 667M 264M 3.34B 252M 247M 10.53B | P/E 2021 |
-3.2x | P/E 2022 | -0.65x |
|---|---|---|---|---|---|
| Enterprise Value | 152M 135M 125M 113M 212M 14.4B 216M 1.51B 596M 7.54B 569M 557M 23.78B | EV / Sales 2021 |
29.1x | EV / Sales 2022 | 7.89x |
| Free-Float |
98.65% | Yield 2021 * |
-
| Yield 2022 | - |
| 1 day | -66.67% | ||
| 1 week | -80.00% | ||
| Current month | -87.50% | ||
| 1 month | -80.00% | ||
| 3 months | -90.00% | ||
| 6 months | -90.91% | ||
| Current year | -96.15% |
| 1 week | 0 |  | 0 |
| 1 month | 0 | | 0 |
| Current year | 0 | | 0.01 |
| 1 year | 0 | | 0.02 |
| 3 years | 0 | | 0.25 |
| 5 years | 0 | | 7.4 |
| 10 years | 0 | | 19.39 |
| Manager | Title | Age | Since |
|---|---|---|---|
Henry Ji
CEO | Chief Executive Officer | 61 | 01/04/2011 |
Scott Schaus
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/2022 |
John Waldheim
LAW | General Counsel | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Henry Ji
CHM | Chairman | 61 | 01/08/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -66.67% | -80.00% | -98.00% | -99.87% | 54.37K | |
| +2.41% | +0.29% | +42.02% | +71.57% | 64.69B | |
| -0.15% | +7.50% | +11.01% | +73.48% | 54.78B | |
| +0.57% | +4.60% | +10.07% | +92.86% | 53.49B | |
| +0.37% | +4.67% | +27.03% | +52.07% | 45.98B | |
| -1.21% | +2.32% | +21.80% | +123.81% | 42.94B | |
| -0.37% | +5.07% | +249.91% | +918.74% | 40.08B | |
| +0.05% | +0.21% | +18.26% | +58.53% | 33.52B | |
| -0.38% | +5.68% | +36.43% | +27.54% | 23.67B | |
| +1.19% | -4.98% | +29.01% | -0.65% | 23.97B | |
| Average | -6.42% | -2.83% | +34.76% | +131.81% | 38.31B | |
| Weighted average by Cap. | +0.39% | +2.73% | +47.57% | +158.58% |
| 2021 | 2022 | |
|---|---|---|
| Net sales | 52.9M 47.24M 43.64M 39.55M 73.99M 5.02B 75.22M 525M 208M 2.63B 199M 194M 8.3B | 62.84M 56.12M 51.84M 46.98M 87.89M 5.97B 89.34M 624M 247M 3.13B 236M 231M 9.85B |
| Net income | -428M -382M -353M -320M -599M -40.66B -609M -4.25B -1.68B -21.3B -1.61B -1.57B -67.16B | -573M -512M -473M -428M -801M -54.38B -814M -5.69B -2.25B -28.49B -2.15B -2.1B -89.83B |
| Net Debt | 111M 98.85M 91.32M 82.76M 155M 10.51B 157M 1.1B 435M 5.51B 415M 407M 17.36B | 84.53M 75.48M 69.73M 63.19M 118M 8.02B 120M 839M 332M 4.2B 317M 310M 13.25B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/10/26 | $0.000100 | -66.67% | 30,712 |
| 22/10/26 | $0.000300 | +50.00% | 8,917 |
| 21/10/26 | $0.000200 | -75.00% | 28,126 |
| 20/10/26 | $0.000800 | +300.00% | 57,250 |
| 19/10/26 | $0.000200 | -60.00% | 28,501 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- SRNE Stock
Select your edition
All financial news and data tailored to specific country editions
